Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — H1 2026 Earnings Presentation
20 slides from Pt Prodia Widyahusada Tbk's earnings presentation, 2026
Slide 1: 1H2026 Company Update
1H2026 Company Update PT Prodia Widyahusada Tbk | PRDA.JK
Slide 2: Disclaimer
This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By viewing all or
Slide 3: Company Overview
S a > a o > O ’ > = © 2. = fe) U
Slide 4: 1H2026 Key Highlights
1H2026 Key Highlights Key Player in Private Independent Clinical Lab chain with 40.0%* market share in Indonesia Start from 2025, Prodia expands networks through strategic Current Initiatives collaboration in SEA Market and optimalization of clinical IDR 1.115 Trillion services USD 62.4 Million Feb
Slide 5: Continuous Improvement in a Challenging Market
Continuous Improvement in a Challenging Market Ensure sustainability business with innovation, growth, and optimization Visits Revenue (in Million) (in IDR Trillion) CAGR* CAGR >3.0 * 2.3 -1.8% 4.0% >2.7 1.9 Prodia has strengthen the fundamental and generated continuous 2020 2021 2022 2023 2024 2025
Slide 6: Business Highlight
© -Phodia: Women’s Health Centre Business Highlight
Slide 7: The Comprehensive Center of Excellence
The Comprehensive Center of Excellence Delivering personalization and precision in multiple customer segments Routine Testing Non-Laboratory Testing Specialty Clinics Esoteric Testing Referral Lab Services Doctor Consultation One-stop shop, Multiomics General Medical Preventive Treatment offering th
Slide 8: Scalable Hub and Spoke Business Model
Scalable Hub and Spoke Business Model Centralized core operations (hub) while efficiently distributing services through multiple outlets (spokes) 4 Referral Labs in Jakarta, Surabaya, Medan, Makassar Significant Economies of Scale Achieved Centralized information with Prodia Clinical Labs, Hospitals
Slide 9: Maintain Strong and Long-Term Relationship
Maintain Strong and Long-Term Relationship Generate new tests and ongoing referrals in partnership with medical & scientific community Strong relationships through the work of Introduced new tests, such as HPV-DNA High Risk Self- more than 500 Marketing and Collection (My HPV Test), Maternal Cell Co
Slide 10: Be The Next Generation Laboratory
Be The Next Generation Laboratory To deliver precision medicine with comprehensive lab services Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Predictive & Separation Science Diagnostic Laboratory Laboratory Next Generation Laboratory Anatomical Pathology Cancer Molecular La
Slide 11: Business Updates
Business Updates
Slide 12: Expand Our Presence with Diverse Models
Expand Our Presence with Diverse Models With strategic expansion of outlets, ensuring proximity to our customers FY2025 1H2026 Digital Platform Optimization 2026 Outlet Development Target >3 Hospital Labs Management 402 392 Outlets Outlets includes hospital lab & genomic site U by Prodia > 20 POC Ou
Slide 13: Financial Updates
Financial Updates
Slide 14: Solid Performance in 1H2026 Revenue
Solid Performance in 1H2026 Revenue Supported by solid growth across customer segments Revenue (Unaudited) Quarterly Revenue (Unaudited) In IDR Billion In IDR Billion 1H21-1H26 CAGR -2.1% 2021 2022 2023 1H25-1H26 2024 2025 2026 1,238 Growth: +8.5% 1,115 1,037 1,063 1,032 1,027 1H2026 revenue 613.3 s
Slide 15: 1H2026 Financial Performance
1H2026 Financial Performance Operational efficiency drives stronger profitability Cost of Revenue (COR) Gross Profit OPEX Net Income in IDR Billion in IDR Billion In IDR Billion In IDR Billion 1H21-1H26 CAGR +0.6% 1H21-1H26 CAGR -3.9% 1H21-1H26 CAGR +6.1% 1H21-1H26 CAGR -23.8% COR to revenue Gross P
Slide 16: 1H2026 Financial Summary
1H2026 Financial Summary Sustained growth with improving profitability (in IDR Bn) 1H2026 1H2025 Change (in IDR Bn) 1H2026 1H2025 Change Revenue 1,114.7 1,027.3 +8.5% Total Asset 2,642.7 2,574.1 +2.7% Gross Profit 628.3 573.3 +9.6% Total Equity 2,341.3 2,314.9 +1.1% EBIT 88.3 63.6 +38.9% EBT 98.6 86
Slide 17: Professional Team & Shares Information
Professional Team & Shares Information
Slide 18: Experienced & Professional Management Team
Experienced & Professional Management Team With more than 20 years experience in delivering growth and innovation of Prodia Years of 54 Years of 54 Years of 43 Years of 39 35 Years of 38 Years of Experience Experience Experience Experience Experience Experience Gunawan Endang Keri KeriLestari Lestar
Slide 19: Shareholders Composition
Shareholders Composition Public free float is 26% of total with market cap of IDR 2.13 Trillion* PT Prodia Utama Bio Majesty Pte. Ltd. Public Treasury Stock 57% 12% 26% 5% 30% Distributor for Contract Research Research, therapy and medical Organization banking of stem cell equipment PT Prodia Widyah
Slide 20: For further Information
For further Information: PT Prodia Widyahusada Tbk Prodia Tower, Jalan Kramat Raya No. 150 Jakarta 10430, Indonesia Email: investor.relation@prodia.co.id
PT Prodia Widyahusada — H1 2026 Earnings Presentation on 6ix